CTOs on the Move


 
  • Number of Employees:
  • Annual Revenue:

  • ,

Executives

Name Title Contact Details

Similar Companies

MACC Investment Group LLC

MACC Investment Group will endeavor to re-energize portfolio brands by providing consistent supportive leadership. We hold our internal support teams accountable to the task of delivering on a mission that supports improving guest transactions concurrent with growing market share. We will develop and coach behaviors that drive performance while holding our corporate team accountable in a business environment that rewards and celebrates improved diligence and fiscal responsibility.

Goodturn Tire & Auto

Goodturn is a family of brands that provide automotive and tire repair and maintenance services. We partner with leading brands who are looking to accelerate their growth while offering greater opportunities for their employees to reach their fullest potential. Our company is built around delivering outstanding customer service and building winning cultures.

RIP-IT

We are a trailblazing brand dedicated to inspiring and empowering women in sports. Our high-performance gear and cutting-edge technology enhance abilities and boost confidence. We create a supportive community that celebrates achievements, fosters connections, and encourages collaboration. Authentic, persevering, and dedicated to excellence, we redefine what it means to be a force in womens sports

IMUNON

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.